Not yet taking people in United StatesPhase 1

Tests a sleep therapy using anesthesia in adults with chronic insomnia

Tests a single anesthesia-induced sleep session in adults with chronic insomnia.

Key facts

Who runs it: Nyree Penn
Where: Aventura, United StatesSee the site
Trial code: NCT06644573
Registry title: Evaluating the Efficacy and Safety of PROSOMNIA Sleep Therapy™ in Patients With Sleep Deprivation and Chronic Insomnia
Status: Not yet recruiting
Phase: Phase 1
People taking part: 100 people, planned
Started: 1 Nov 2025
Planned end: 1 May 2026
Type of study: Interventional
Treatments tested: PROSOMNIA Sleep Therapy™ (PSTx)
Anesthesia-Induced Sleep Therapy
Diprivan (propofol), Astra-Zeneca
Continuous EEG Monitoring
Record updated: 28 May 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 65 with chronic insomnia, sleep deprivation or REM sleep problems who did not improve with usual sleep treatments. Everyone gets one anesthesia-induced sleep session.

Age: 18 to 65 years
Sex: All sexes can join.
Disease stage: Chronic insomnia, sleep deprivation or REM sleep problems, diagnosed or not yet diagnosed.
Earlier treatment: People who did not get relief from usual sleep treatments. Current use of sedatives and sleeping pills (benzodiazepines, Z-drugs, barbiturates) is not allowed.

Main reasons for not taking part

Severe obesity (BMI over 40)
Heart or blood vessel conditions
Neurological disorders, such as epilepsy
Any condition that makes anesthesia unsafe, or ASA status above II
Pregnancy or breastfeeding

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

Age Range: 18-65 years of age Reason: This age range includes adults who are most likely to benefit from the PROSOMNIA Sleep therapy and who can provide informed consent. It also excludes children and older adults who may have different physiological responses or additional health risks
Diagnosed or Undiagnosed Chronic Insomnia:; Reason: Included subjects have a consistent pattern of sleep disturbances that PROSOMNIA Sleep Therapy aims to treat
Diagnosed or Undiagnosed Sleep Deprivation:; Reason: Includes individuals who are not getting enough sleep quantity, which is a key condition that the PROSOMNIA Sleep Therapy aims to address
Diagnosed or Undiagnosed REM Sleep Inconsistencies:; Reason: Includes individuals who are not getting enough sleep quality and those with specific REM sleep phase issues that the PROSOMNIA Sleep Therapy is designed to improve
Failure to Respond to Conventional Sleep Treatments:; Reason: Focuses on subjects who have not found relief from existing sleep therapies, ensuring that the study population represents those in need of alternative solutions
Ability to Provide Informed Consent:; Reason: Ensures that participants understand the study and agree to participate voluntarily

Who cannot take part

Current Use of Prohibited Medications:; Reason: Medications that could interfere with the combined use of anesthesia including, but not limited to sedatives and hypnotics; such as benzodiazepines, Z-drugs and barbiturates
Pregnancy or Breastfeeding:; Reason: Ensures the safety of the fetus or infant, as the effects of the PROSOMNIA Sleep therapy on pregnancy or lactation are unknown
Cardiovascular Conditions:; Reason: Patients with significant heart conditions are at higher risk for complications during anesthesia
Neurological Disorders:; Reason: These diagnosed conditions and medications such as epilepsy could interfere with sleep patterns and responses to sleep therapy
Other Health Conditions Contraindicating Anesthesia:; Reason: Includes any condition that would make the use of anesthesia unsafe
Greater than ASA II Status:; Reason: The American Society of Anesthesiologists (ASA) physical status classification system classifies patients based on their pre-anesthesia medical conditions. Excluding those above ASA II ensures that only patients with mild systemic disease are included, to minimize risks
Severe Obesity (BMI \> 40):; Reason: Severe obesity can increase the risk of complications with anesthesia and may affect sleep patterns in ways that could confound study results

Other criteria

By adhering to the following criteria, the study aims to select a population that can safely undergo the PROSOMNIA Sleep therapy and for whom the therapy is most likely to be beneficial, ensuring the reliability and validity of the study outcomes

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 65 years old?

Where in United States

PROSOMNIA Sleep Health and WellnessAventura, United StatesContact: Nyree Penn, MHSc., CAA, Master of Health ScienceNo longer taking part

About the trial

What the trial wants to find out

This clinical trial aims to evaluate the safety and efficacy of PROSOMNIA Sleep Therapy (PSTx) for individuals suffering from chronic insomnia, sleep deprivation, and REM sleep disorders. Chronic insomnia, characterized by difficulty falling or staying asleep, significantly affects patients and quality of life, mood, and cognitive function. REM sleep disorders, in which the body struggles to enter or maintain restful REM sleep, can worsen these issues. The trial introduces a novel therapy using anesthesia-induced sleep, targeting sleep homeostasis and improving sleep architecture.

Read full original descriptionShow less

Objectives: The primary goals of the trial are to determine:

1. Whether PROSOMNIA Sleep Therapy increases the quality of REM sleep. 2. Whether PSTx increases the duration of REM and/or NREM sleep. 3. Whether PSTx decreases the time it takes participants to fall asleep (sleep onset latency).

Participants will receive ONE (1) PROSOMNIA Sleep Therapy session lasting between 60-120 minutes. Each session uses Diprivan/Propofol to induce sleep, and is monitored via an EEG to ensure proper sleep stages, particularly REM sleep.

Participant Criteria:

Inclusion: Adults aged 18-65 with diagnosed or undiagnosed chronic insomnia or sleep deprivation.

Exclusion: Patients with severe obesity, significant cardiovascular, neurological, or psychiatric conditions, or those with an ASA status above II.

Study Design: This trial is non-randomized, single-arm and open-label, with all participants receiving the PSTx. The trial does not include a comparison group, as the focus is on evaluating the immediate, direct effects of the therapy.

Participants will undergo continuous EEG monitoring during therapy sessions, allowing researchers to track brain activity and sleep stages in real-time. This method ensures that sleep cycles, particularly REM sleep, are optimized for therapeutic benefit.

Therapy Methodology:

PROSOMNIA Sleep Therapy leverages anesthesia to mimic natural sleep patterns and enhance the efficiency of REM sleep. Diprivan/Propofol is used to induce REM sleep, while EEG monitoring tracks and maintains proper sleep architecture throughout the session. The therapy promotes the clearance of adenosine, a compound that builds up during wakefulness and drives the need for sleep. Adenosine is cleared during REM sleep, reducing sleep pressure and improving cognitive function.

Outcome Measures:

Primary Outcomes: Researchers will measure the increase in REM sleep duration, improvement in sleep quality (via self-reported questionnaires), and a reduction in sleep onset latency.

Secondary Outcomes: These include changes in mood, cognitive function, and blood serum uric acid levels. Patient-reported outcomes will also be tracked through tools like the PROSOMNIA Sleep Quiz, which is specifically designed for PSTx.

Significance: Chronic insomnia and REM sleep disorders affect millions globally, leading to cognitive impairment, mood disturbances, and poor overall health. Traditional treatments, including pharmacological approaches and Cognitive Behavioral Therapy for Insomnia (CBT-I), often provide suboptimal results for many individuals. PSTx offers a novel, therapeutic approach to restoring sleep balance and enhancing the overall quality of sleep, particularly for those who have not responded to conventional treatments.

Study Process:

Recruitment and Baseline Assessments: Participants undergo a comprehensive sleep assessment, including sleep questionnaires and polysomnography, to establish a baseline for sleep quality and duration. Blood serum uric acid levels will also be measured to track any biochemical changes due to therapy.

Therapy Sessions: Only one (1) PROSOMNIA Sleep Therapy session will be administered, with the session lasting between 60-120 minutes. Diprivan/Propofol is used to induce sleep, and EEG will monitor brain activity to ensure the proper balance of sleep stages.

Post-Therapy Follow-up: Follow-up assessments will occur at 24 hours, 7 days, and 30 days post-treatment. Researchers will analyze the therapy effects on REM sleep, mood, cognitive function, and other health indicators.

Potential Implications: If successful, this trial could revolutionize how we treat sleep disorders by targeting the underlying mechanisms of sleep pressure and REM sleep disruption. PROSOMNIA Sleep Therapy may offer a safe, effective, and immediate alternative for patients who have exhausted other treatment options.

Key Concepts:

Homeostatic sleep drive, (Process S), caused by adenosine buildup during wakefulness, is disrupted by chronic insomnia. This impacts cognitive function health and recovery. Anesthesia-induced REM sleep via PSTx helps regulate this homeostatic sleep stage, offering deeper and more restorative sleep compared to other sleep therapies. The study uses statistical methods like ANOVA and Chi-square to measure outcomes.

The group in the trial

Single-Arm - PROSOMNIA Sleep TherapyTreatment being tested
Description: All eligible participants in this study will be assigned to a single arm and receive the same intervention, PROSOMNIA Sleep Therapy. This involves a controlled, anesthesia-induced sleep session using Diprivan/Propofol, administered under the supervision of an Anesthesiologist. Monitoring will include American Society of Anesthesiologists (ASA) standard monitoring and real-time EEG to track sleep stages and brain activity during the procedure. Interventions: PROSOMNIA Sleep Therapy, involving the administration of Diprivan/Propofol, a FDA-approved anesthetic, to induce sleep in individuals with chronic insomnia, sleep deprivation and/or REM sleep disparities. This treatment is intended to reduce sleep pressure, decrease sleep onset latency, enhance REM sleep duration, and improve overall sleep quality. Continuous EEG monitoring to track sleep architecture and blood serum uric acid tests to identify adenosine release.
Treatment: PROSOMNIA Sleep Therapy™ (PSTx), Anesthesia-Induced Sleep Therapy, Diprivan (propofol), Astra-Zeneca, and Continuous EEG Monitoring